OM1 is a company based in the United States that operates within the software industry, specifically focusing on applications relevant to the biotech and pharmaceuticals sectors. Founded in 2015, the company employs between 51 and 200 individuals and has reported revenue of approximately $30 million. OM1's expertise encompasses the development of software solutions that facilitate data analysis and insights in healthcare, particularly in the context of patient outcomes and treatment efficacy. A notable document published by the company is a research article that examines mammographic screening practices, specifically a multisite study of digital breast tomosynthesis. This document reflects OM1's commitment to advancing research and understanding in the medical field, particularly regarding diagnostic technologies. While the company's document corpus is currently limited, its focus on integrating software with healthcare research positions it within the intersection of technology and life sciences, aiming to enhance the quality of patient care through data-driven insights.